Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ARVN

ARVN - Arvinas Inc Stock Price, Fair Value and News

25.64USD-0.81 (-3.06%)Market Closed

Market Summary

ARVN
USD25.64-0.81
Market Closed
-3.06%

ARVN Alerts

  • Big fall in Revenue (Y/Y)
  • Losses in recent quarter

ARVN Stock Price

View Fullscreen

ARVN RSI Chart

ARVN Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-4.95

Price/Sales (Trailing)

22.35

EV/EBITDA

-4.8

Price/Free Cashflow

-4.93

ARVN Price/Sales (Trailing)

ARVN Profitability

EBT Margin

-448.41%

Return on Equity

-58.19%

Return on Assets

-29.26%

Free Cashflow Yield

-20.29%

ARVN Fundamentals

ARVN Revenue

Revenue (TTM)

78.5M

Rev. Growth (Yr)

-22.15%

Rev. Growth (Qtr)

-15.53%

ARVN Earnings

Earnings (TTM)

-354.8M

Earnings Growth (Yr)

15.26%

Earnings Growth (Qtr)

55.17%

Breaking Down ARVN Revenue

Last 7 days

-3.9%

Last 30 days

-20.7%

Last 90 days

-42.8%

Trailing 12 Months

-15.5%

How does ARVN drawdown profile look like?

ARVN Financial Health

Current Ratio

4.94

Debt/Equity

0

Debt/Cashflow

-505.86

ARVN Investor Care

Shares Dilution (1Y)

28.15%

Diluted EPS (TTM)

-6.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
2023137.3M158.1M159.4M78.5M
202274.5M102.8M126.8M131.3M
202125.2M24.9M26.6M53.5M
202045.2M46.9M24.5M25.9M
201914.2M14.8M41.5M43.0M
201810.0M11.7M13.5M14.3M
20170007.6M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Arvinas Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 29, 2024
norwalk leslie v
acquired
-
-
5,899
-
May 29, 2024
cunningham everett
acquired
-
-
5,899
-
May 29, 2024
morrison briggs
acquired
-
-
5,899
-
May 29, 2024
smaldone alsup laurie
acquired
-
-
5,899
-
May 29, 2024
bain linda
acquired
-
-
5,899
-
May 29, 2024
agarwal sunil
acquired
-
-
5,899
-
May 29, 2024
kennedy edward moore jr.
acquired
-
-
5,899
-
May 29, 2024
young john d
acquired
-
-
5,899
-
May 21, 2024
teel randy
acquired
-
-
13,300
int. chief financial officer
Mar 18, 2024
berkowitz noah
acquired
-
-
63,452
chief medical officer

1–10 of 50

Which funds bought or sold ARVN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 04, 2024
DekaBank Deutsche Girozentrale
unchanged
-
-28,000
1,736,000
-%
May 29, 2024
Opaleye Management Inc.
added
25.14
2,768,510
13,622,400
2.97%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
105
277,282
539,282
0.07%
May 20, 2024
Virtu Financial LLC
sold off
-100
-266,000
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
17.5
356,584
2,355,400
-%
May 16, 2024
CASTLEARK MANAGEMENT LLC
added
7.57
232,326
3,178,150
0.13%
May 16, 2024
JANE STREET GROUP, LLC
added
12.82
526,056
4,527,510
-%
May 16, 2024
COMERICA BANK
reduced
-15.9
-1,256
6,770
-%
May 15, 2024
Engineers Gate Manager LP
added
358
1,593,050
2,036,100
0.05%
May 15, 2024
HighVista Strategies LLC
new
-
2,110,320
2,110,320
0.75%

1–10 of 45

Are Funds Buying or Selling ARVN?

Are funds buying ARVN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ARVN
No. of Funds

Unveiling Arvinas Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
price t rowe associates inc /md/
5.6%
3,835,364
SC 13G
Feb 14, 2024
ecor1 capital, llc
9.99%
6,800,493
SC 13G/A
Feb 14, 2024
rtw investments, lp
6.2%
4,213,483
SC 13G
Feb 13, 2024
avidity partners management lp
4.4%
2,985,117
SC 13G/A
Feb 13, 2024
vanguard group inc
7.13%
4,851,390
SC 13G/A
Jan 26, 2024
blackrock inc.
7.9%
5,353,605
SC 13G/A
Dec 11, 2023
fmr llc
-
0
SC 13G/A
Feb 14, 2023
avidity partners management lp
9.3%
4,950,000
SC 13G/A
Feb 14, 2023
price t rowe associates inc /md/
4.4%
2,368,130
SC 13G/A
Feb 13, 2023
ecor1 capital, llc
5.9%
3,123,300
SC 13G/A

Recent SEC filings of Arvinas Inc

View All Filings
Date Filed Form Type Document
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 30, 2024
8-K
Current Report
May 30, 2024
8-K
Current Report

Peers (Alternatives to Arvinas Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Arvinas Inc News

Latest updates
Defense World20 hours ago
Seeking Alpha3 months ago

Arvinas Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-15.5%25,300,00029,950,00034,600,00054,500,00032,500,00037,850,00033,200,00033,800,00026,500,00033,250,0009,300,0005,500,0005,500,0006,315,9157,596,7765,747,6816,239,6284,893,27330,050,2274,016,4894,016,489
Operating Expenses-11.1%108,600,000122,200,000108,500,000129,100,000120,200,000113,350,00097,500,00099,600,00084,200,00080,750,00056,600,00057,400,00047,200,00045,471,90239,344,84332,231,56429,651,69127,683,17324,545,41422,441,41719,830,988
  S&GA Expenses-10.2%24,300,00027,050,00022,600,00025,700,00024,900,00015,100,00020,000,00024,300,00020,200,00018,850,00016,000,00014,400,00012,300,00012,227,5969,331,9258,815,4747,925,0057,268,3907,957,3646,440,7795,640,629
  R&D Expenses-11.4%84,300,00095,150,00085,900,000103,400,00095,300,00098,250,00077,500,00075,300,00064,000,00061,900,00040,600,00043,000,00034,900,00033,244,30630,012,91823,416,09021,726,68620,414,78316,588,05016,000,63814,190,359
EBITDA Margin3.3%-4.42-4.57-1.73-1.72-1.97-1.86-1.36-1.72-2.39-3.35-4.11-4.41---------
Interest Expenses-------6,350,0003,400,0001,800,0001,200,000-1,100,000300,000400,000500,00051,25016,25016,25016,25016,25022,90322,77823,638
Income Taxes-93.7%100,0001,600,000--300,000-400,00010,800,0002,200,0003,400,0004,500,000------------
Earnings Before Taxes54.8%-69,300,000-153,200,000-63,900,000-65,600,000-81,200,000-69,250,000-61,100,000-64,100,000-56,600,000------------
EBT Margin3.3%-4.48-4.64-1.76-1.75-2.01-1.91-1.45-1.79-2.47-3.44-4.33-4.62---------
Net Income55.2%-69,400,000-154,800,000-64,000,000-66,600,000-81,900,000-82,900,000-66,200,000-70,000,000-63,400,000-52,950,000-46,800,000-50,300,000-41,000,000-41,514,424-30,819,866-25,226,539-21,739,171-21,047,716-17,675,373-17,164,646-14,404,492
Net Income Margin3.4%-4.52-4.68-1.85-1.88-2.19-2.15-1.99-2.27-2.86-3.57-6.75-6.57---------
Free Cashflow-17.3%-97,600,000-83,200,000-85,900,000-89,300,000-92,300,000-72,300,000-68,800,000-80,000,000-59,200,000-37,600,000680,200,000-47,900,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-7.1%1,2131,3051,0581,0841,1761,2691,3351,4071,4881,5821,605644682717272263282302209172187
  Current Assets-7.0%1,1901,2801,0331,0571,1481,2401,3051,3761,4571,5531,576628665703258250270291200163180
    Cash Equivalents-71.8%88.0031211491.0013087.0013393.0062.0010826053.0034658889.0022.0036.009.0012.0011.0029.00
  Net PPE-9.6%10.0012.0013.0013.0013.0013.0014.0014.0013.0013.0012.0012.0012.0012.0012.0011.0010.008.007.006.004.00
Liabilities-6.5%60364560162066570471373676580078761.0066.0075.0067.0065.0071.0075.0075.0056.0059.00
  Current Liabilities-6.3%24125731730728329524523823826218342.0040.0049.0040.0034.0033.0033.0029.0021.0021.00
  Long Term Debt-12.5%1.001.001.001.001.001.001.001.001.001.001.001.002.002.002.002.002.002.002.002.002.00
    LT Debt, Current0%0.000.000.000.000.00--------------0.000.00
    LT Debt, Non Current-12.5%1.001.001.001.001.001.001.001.001.001.001.001.002.002.002.002.002.002.002.002.002.00
Shareholder's Equity-7.6%610660457464511565622671723782818583615642205198212227134117128
  Retained Earnings-5.2%-1,402-1,332-1,177-1,113-1,047-965-882-816-746-682-629-583-532-491-450-419-394-372-351-333-316
  Additional Paid-In Capital1.0%2,0161,9961,6441,5901,5711,5491,5291,5091,4881,4691,4481,1671,1481,134654616607599485450444
Shares Outstanding0.4%68.0068.0055.0053.0053.0053.0053.0053.0053.0050.0050.0049.00---------
Float----1,293---2,176---3,457---1,348---465-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-17.3%-97,500-83,100-84,800-88,700-91,200-71,200-66,600-78,600-57,100-35,700681,500-47,400-39,000-28,964-22,383-21,401-16,949-16,1521,854-13,569-12,732
  Share Based Compensation11.4%18,60016,70016,70018,30019,90020,10018,80020,00016,60017,00015,20014,60010,3008,0788,2477,7556,1205,0094,6015,3135,177
Cashflow From Investing-138.0%-127,800-53,70070,00048,600138,60019,400105,800109,0008,600-115,600-741,100-249,100-207,80056,91259,2835,61042,495-95,431-31,814-4,22838,374
Cashflow From Financing-99.5%1,600334,80037,9005001,5005001,2005002,5003,900266,6003,6004,500471,47530,4961,2791,350108,63830,754353-45.54
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ARVN Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue$ 25.3$ 32.5
Operating expenses:  
Research and development84.395.3
General and administrative24.324.9
Total operating expenses108.6120.2
Loss from operations(83.3)(87.7)
Other income (expense)  
Other expense, net0.0(1.1)
Interest income, net14.07.6
Total other income14.06.5
Net loss before income taxes and loss from equity method investment(69.3)(81.2)
Income tax (expense) benefit(0.1)0.4
Loss from equity method investment0.0(1.1)
Net loss$ (69.4)$ (81.9)
Net loss per common share, basic (in dollars per share)$ (0.97)$ (1.54)
Net loss per common share, diluted (in dollars per share)$ (0.97)$ (1.54)
Weighted average common shares outstanding, basic (in shares)71.753.3
Weighted average common shares outstanding, diluted (in shares)71.753.3
Statement of Comprehensive Income [Abstract]  
Net loss$ (69.4)$ (81.9)
Other comprehensive loss:  
Unrealized (loss) gain on available-for-sale securities(1.3)6.6
Comprehensive loss$ (70.7)$ (75.3)

ARVN Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 88.0$ 311.7
Restricted cash5.55.5
Marketable securities1,081.3949.3
Other receivables7.17.2
Prepaid expenses and other current assets8.46.5
Total current assets1,190.31,280.2
Property, equipment and leasehold improvements, net10.411.5
Operating lease right of use assets2.02.5
Collaboration contract asset and other assets9.910.4
Total assets1,212.61,304.6
Current liabilities:  
Accounts payable and accrued liabilities76.492.2
Deferred revenue162.9163.0
Current portion of operating lease liabilities1.51.9
Total current liabilities240.8257.1
Deferred revenue361.0386.2
Long term debt0.70.8
Operating lease liabilities0.40.5
Total liabilities602.9644.6
Commitments and Contingencies (Note 13)
Stockholders’ equity:  
Preferred stock, $0.001 par value, zero shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively0.00.0
Common stock, $0.001 par value; 68.3 and 68.0 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively0.10.1
Accumulated deficit(1,402.1)(1,332.7)
Additional paid-in capital2,016.11,995.7
Accumulated other comprehensive loss(4.4)(3.1)
Total stockholders’ equity609.7660.0
Total liabilities and stockholders’ equity$ 1,212.6$ 1,304.6
ARVN
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
 CEO
 WEBSITEarvinas.com
 INDUSTRYBiotechnology
 EMPLOYEES415

Arvinas Inc Frequently Asked Questions


What is the ticker symbol for Arvinas Inc? What does ARVN stand for in stocks?

ARVN is the stock ticker symbol of Arvinas Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arvinas Inc (ARVN)?

As of Fri Jun 14 2024, market cap of Arvinas Inc is 1.75 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARVN stock?

You can check ARVN's fair value in chart for subscribers.

What is the fair value of ARVN stock?

You can check ARVN's fair value in chart for subscribers. The fair value of Arvinas Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arvinas Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARVN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arvinas Inc a good stock to buy?

The fair value guage provides a quick view whether ARVN is over valued or under valued. Whether Arvinas Inc is cheap or expensive depends on the assumptions which impact Arvinas Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARVN.

What is Arvinas Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, ARVN's PE ratio (Price to Earnings) is -4.95 and Price to Sales (PS) ratio is 22.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARVN PE ratio will change depending on the future growth rate expectations of investors.